Literature DB >> 24509741

Master Protocol for squamous cell lung cancer readies for launch.

Jeffrey L Fox.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24509741     DOI： 10.1038/nbt0214-116b

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Biomarker-led adaptive trial blazes a trail in breast cancer.

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2010-05       Impact factor: 54.908
  1 in total
  4 in total

1.  NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Authors:  Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2014-11       Impact factor: 11.908

2.  NCI-MATCH pairs tumor mutations with matching drugs.

Authors:  Vicki Brower
Journal:  Nat Biotechnol       Date:  2015-08       Impact factor: 54.908

3.  A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers.

Authors:  Alexander Drilon; Hirofumi Sugita; Camelia S Sima; Marjorie Zauderer; Charles M Rudin; Mark G Kris; Valerie W Rusch; Christopher G Azzoli
Journal:  J Thorac Oncol       Date:  2014-09       Impact factor: 15.609

Review 4.  Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics.

Authors:  Saumya Pant; Russell Weiner; Matthew J Marton
Journal:  Front Oncol       Date:  2014-04-17       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.